M Ferdaoussi1,2, V Bergeron1,2, B Zarrouki1,2, J Kolic3, J Cantley4, J Fielitz5,6, E N Olson7, M Prentki1,8, T Biden4, P E MacDonald3, V Poitout9,10,11. 1. Montreal Diabetes Research Center, CRCHUM, Technopole Angus, 2901 Rachel Est, Montréal, QC, Canada, H1W 4A4. 2. Department of Medicine, University of Montreal, Montreal, QC, Canada. 3. Department of Pharmacology and the Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada. 4. Garvan Institute of Medical Research, St Vincent's Hospital, Darlinghurst, Sydney, NSW, Australia. 5. Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany. 6. Medical Department, Division of Cardiology, Charité University, Campus Virchow-Klinikum, Berlin, Germany. 7. Departments of Molecular Biology, Internal Medicine, and Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 8. Departments of Nutrition and Biochemistry, University of Montreal, Montreal, QC, Canada. 9. Montreal Diabetes Research Center, CRCHUM, Technopole Angus, 2901 Rachel Est, Montréal, QC, Canada, H1W 4A4. Vincent.poitout@umontreal.ca. 10. Department of Medicine, University of Montreal, Montreal, QC, Canada. Vincent.poitout@umontreal.ca. 11. Departments of Nutrition and Biochemistry, University of Montreal, Montreal, QC, Canada. Vincent.poitout@umontreal.ca.
Abstract
AIMS/HYPOTHESIS: Activation of the G protein-coupled receptor (GPR)40 by long-chain fatty acids potentiates glucose-stimulated insulin secretion (GSIS) from pancreatic beta cells, and GPR40 agonists are in clinical development for type 2 diabetes therapy. GPR40 couples to the G protein subunit Gα(q/11) but the signalling cascade activated downstream is unknown. This study aimed to determine the mechanisms of GPR40-dependent potentiation of GSIS by fatty acids. METHODS: Insulin secretion in response to glucose, oleate or diacylglycerol (DAG) was assessed in dynamic perifusions and static incubations in islets from wild-type (WT) and Gpr40 (-/-) mice. Depolymerisation of filamentous actin (F-actin) was visualised by phalloidin staining and epifluorescence. Pharmacological and molecular approaches were used to ascertain the roles of protein kinase D (PKD) and protein kinase C delta in GPR40-mediated potentiation of GSIS. RESULTS: Oleate potentiates the second phase of GSIS, and this effect is largely dependent upon GPR40. Accordingly, oleate induces rapid F-actin remodelling in WT but not in Gpr40 (-/-) islets. Exogenous DAG potentiates GSIS in both WT and Gpr40 (-/-) islets. Oleate induces PKD phosphorylation at residues Ser-744/748 and Ser-916 in WT but not Gpr40 (-/-) islets. Importantly, oleate-induced F-actin depolymerisation and potentiation of GSIS are lost upon pharmacological inhibition of PKD1 or deletion of Prkd1. CONCLUSIONS/ INTERPRETATION: We conclude that the signalling cascade downstream of GPR40 activation by fatty acids involves activation of PKD1, F-actin depolymerisation and potentiation of second-phase insulin secretion. These results provide important information on the mechanisms of action of GPR40, a novel drug target for type 2 diabetes.
AIMS/HYPOTHESIS: Activation of the G protein-coupled receptor (GPR)40 by long-chain fatty acids potentiates glucose-stimulated insulin secretion (GSIS) from pancreatic beta cells, and GPR40 agonists are in clinical development for type 2 diabetes therapy. GPR40 couples to the G protein subunit Gα(q/11) but the signalling cascade activated downstream is unknown. This study aimed to determine the mechanisms of GPR40-dependent potentiation of GSIS by fatty acids. METHODS: Insulin secretion in response to glucose, oleate or diacylglycerol (DAG) was assessed in dynamic perifusions and static incubations in islets from wild-type (WT) and Gpr40 (-/-) mice. Depolymerisation of filamentous actin (F-actin) was visualised by phalloidin staining and epifluorescence. Pharmacological and molecular approaches were used to ascertain the roles of protein kinase D (PKD) and protein kinase C delta in GPR40-mediated potentiation of GSIS. RESULTS:Oleate potentiates the second phase of GSIS, and this effect is largely dependent upon GPR40. Accordingly, oleate induces rapid F-actin remodelling in WT but not in Gpr40 (-/-) islets. Exogenous DAG potentiates GSIS in both WT and Gpr40 (-/-) islets. Oleate induces PKD phosphorylation at residues Ser-744/748 and Ser-916 in WT but not Gpr40 (-/-) islets. Importantly, oleate-induced F-actin depolymerisation and potentiation of GSIS are lost upon pharmacological inhibition of PKD1 or deletion of Prkd1. CONCLUSIONS/ INTERPRETATION: We conclude that the signalling cascade downstream of GPR40 activation by fatty acids involves activation of PKD1, F-actin depolymerisation and potentiation of second-phase insulin secretion. These results provide important information on the mechanisms of action of GPR40, a novel drug target for type 2 diabetes.
Authors: M Leitges; M Mayr; U Braun; U Mayr; C Li; G Pfister; N Ghaffari-Tabrizi; G Baier; Y Hu; Q Xu Journal: J Clin Invest Date: 2001-11 Impact factor: 14.808
Authors: Richard T Waldron; Giulio Innamorati; M Eugenia Torres-Marquez; James Sinnett-Smith; Enrique Rozengurt Journal: Cell Signal Date: 2011-12-29 Impact factor: 4.315
Authors: Thierry Alquier; Marie-Line Peyot; Martin G Latour; Melkam Kebede; Christina M Sorensen; Stephane Gesta; C Ronald Kahn; Richard D Smith; Thomas L Jetton; Thomas O Metz; Marc Prentki; Vincent Poitout Journal: Diabetes Date: 2009-08-31 Impact factor: 9.461
Authors: Petr Ježek; Blanka Holendová; Martin Jabůrek; Jan Tauber; Andrea Dlasková; Lydie Plecitá-Hlavatá Journal: Antioxidants (Basel) Date: 2021-01-29
Authors: Mourad Ferdaoussi; Xiaoqing Dai; Mette V Jensen; Runsheng Wang; Brett S Peterson; Chao Huang; Olga Ilkayeva; Nancy Smith; Nathanael Miller; Catherine Hajmrle; Aliya F Spigelman; Robert C Wright; Gregory Plummer; Kunimasa Suzuki; James P Mackay; Martijn van de Bunt; Anna L Gloyn; Terence E Ryan; Lisa D Norquay; M Julia Brosnan; Jeff K Trimmer; Timothy P Rolph; Richard G Kibbey; Jocelyn E Manning Fox; William F Colmers; Orian S Shirihai; P Darrell Neufer; Edward T H Yeh; Christopher B Newgard; Patrick E MacDonald Journal: J Clin Invest Date: 2015-09-21 Impact factor: 14.808